Orthopedics

Your Article Summary

See Latest Articles

New selective estrogen and androgen receptor modulators
Current Opinion in Rheumatology, 06/12/09

Clarke BL et al. - Lasofoxifene and arzoxifene are two newer SERMs that have recently been demonstrated to improve bone mineral density and lower serum cholesterol values compared with older SERMs in smaller clinical trials. SARMs are a newer category of drug still being investigated mostly at the basic and preclinical level, with fewer clinical trials available for review. SARMs are currently being investigated mostly for use in prostate cancer at different stages but hold promise for multiple other applications.

Related Articles

See all related articles

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Therapeutics and Clinical Risk Management, 10/16/09    Relevance Score: 91%

Today in Bone Metabolism...keeping you current

Receive free subspecialty "5-minute updates" via email

Ubiquitous overexpression of Hey1 transcription factor leads to osteopenia and chondrocyte hypertrophy in bone
Bone , 12/11/09

Gene expression profile in osteoclasts from patients with Pagets disease of bone
Bone , 12/11/09

Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression
Bone , 12/11/09

 See all of Bone Metabolism

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

No anti-angiogenic effect of clinical dosing regimens of a single zoledronic acid injection in an experimental bone healing site
Bone , 12/11/09

Synvisc-One for the treatment of knee osteoarthritis
International Journal of Clinical Rheumatology, 12/07/09

Glenohumeral Chondrolysis After Shoulder Arthroscopy Associated With Continuous Bupivacaine Infusion
Arthroscopy, 12/04/09

 See all of Clinical Pharmacology